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Abstract
The aim of this study was to quantify the value of clinical predictors available in the emergency department (ED) in predicting Streptococcus
pneumoniae as the cause of community-acquired pneumonia (CAP). A prospective, observational, cohort study of patients with CAP
presenting in the ED was performed. Pneumococcal aetiology of CAP was based on either bacteraemia, or S. pneumoniae being cultured
from sputum, or urinary immunochromatographic assay positivity, or positivity of a novel serotype-specific urinary antigen detection test.
Multivariate logistic regression was used to identify independent predictors and various cut-off values of probability scores were used to
evaluate the usefulness of the model. Three hundred and twenty-eight (31.0%) of 1057 patients with CAP had pneumococcal CAP. Nine
independent predictors for pneumococcal pneumonia were identified, but the clinical utility of this prediction model was disappointing,
because of low positive predictive values or a small yield. Clinical criteria have insufficient diagnostic capacity to predict pneumococcal CAP.
Rapid antigen detection tests are needed to diagnose S. pneumoniae at the time of hospital admission.
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Introduction
Streptococcus pneumoniae is the most common causative
pathogen of community-acquired pneumonia (CAP), being
responsible for 20–38% of CAP cases, depending on the
population, use of microbiological tests, and definition of
‘causative pathogen’ [1–4]. Antibiotic treatment recommen-
dations for CAP have changed in recent years. The current
treatment recommendations for CAP are based on the clinical
severity of disease, rather than on the presumed aetiology, and
recommend combinations of b-lactams and macrolides, or
monotherapy with quinolones, for patients hospitalized with
CAP [5–8]. This implies that most patients with pneumococcal
pneumonia now receive broad-spectrum antibiotics. Extensive
use of antibiotics could lead to superinfections with antibi-
otic-resistant pathogens or selection of antibiotic resistance,
and will increase healthcare costs [9,10]. Ideally, patients with
pneumococcal pneumonia would be treated with nar-
row-spectrum antibiotics, which would necessitate accurate
prediction of pneumococcal CAP at the time of antibiotic
prescription. Prediction of CAP aetiology at the time of clinical
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presentation has been attempted before, with huge heteroge-
neity in approaches and results [11–16].
Recently, a new serotype-specific urinary antigen
detection test (UAD) with high sensitivity and specificity
has been clinically validated [17,18]. Using this test, in
combination with the immunochromatographic assay (ICA)
of BinaxNOW (Alere, Waltham, MA, USA), increased the
proportion of patients diagnosed with pneumococcal CAP
from 23.5% to 32.6%. With this optimized diagnostic
approach for pneumococcal CAP, we aimed to develop a
clinical prediction rule for diagnosing pneumococcal CAP in
the emergency department (ED) in order to allow empirical
treatment with narrow-spectrum antibiotics.
Materials and Methods
Patients
We conducted a prospective, observational, cohort study
between January 2008 and April 2009. Adult patients
(≥18 years) with a clinical suspicion of CAP presenting at
the EDs of 23 Dutch hospitals were eligible. A clinical
suspicion of CAP was defined as the presence of at least
two of the following criteria: fever/hypothermia, cough/
change in chronic coughing pattern, dyspnoea/tachypnoea/
hypoxia, findings on percussion/auscultation consistent with
pneumonia, leukocytosis/leukopenia, and/or shift to the left
or an infiltrate(s) on the chest X-ray. Patients with recent
hospitalization or residing in a nursing home, with known
bronchial obstruction or a history of post-obstructive
pneumonia, patients with primary lung cancer or another
malignancy metastatic to the lungs, patients with AIDS,
known or suspected Pneumocystis jerovicii pneumonia or
known or suspected tuberculosis and unconscious patients
were excluded. The study was approved by all local
Research Ethics Committees, and written informed consent
was obtained from all participants or family members.
A subset of the patients in this study with radiographically
confirmed CAP and strict inclusion and exclusion criteria
(n = 776) were used to validate the novel UAD [18].
Diagnostic approach
Standard diagnostic procedures included microbiological cul-
tures of blood, sputum, and pleural fluid (if present), and, for
study purposes, a urine sample was collected within 48 h after
admission.
Urine samples were processed locally: samples were frozen
at 70°C until being processed in the laboratory of Pfizer
Vaccine Research (Pearl River, NY, USA). Here, both the UAD
and the commercially available ICA (Alere) were performed
batchwise by two technicians blinded to any clinical informa-
tion. A third analyst interpreted the results when the first two
analysts did not agree. The UAD is a Luminex technol-
ogy-based multiplex urinary antigen detection assay that can
simultaneously detect 13 different serotypes of S. pneumoniae
by capturing serotype-specific polysaccharides secreted in
human urine. In addition to an enhanced capacity to determine
infections caused by one of those 13 pneumococcal serotypes
(as compared with episodes yielding pneumococci from blood
or other sterile body sites for serotyping), this test also has
41% higher sensitivity than the conventional ICA [17,18].
However, at the moment, this test is only available for
research purposes.
Microbiological testing (blood, sputum cultures and Binax-
NOW Legionella on urine, if clinically applicable) was
performed in local laboratories according to local and
manufacturers’ protocols, with technicians unaware of the
patient’s clinical condition. When no urine sample was stored
for central processing, the ICA results of the local laboratory
were used to define aetiology.
Determinants
Data were collected from the medical chart, during admission
or shortly afterwards, and documented in a standardized case
record form by trained research nurses and/or physicians.The
possible predictors were selected from the literature and
because they were easily available in the ED (for a complete
overview, see Table 2) [13,14,16]. Information on previous
pneumococcal vaccination was also collected, but this was not
considered to be a potential predictor, as it is rarely used in
The Netherlands.
Definition of CAP
CAP was defined as the presence of an infiltrate on the chest
X-ray at the moment of presentation to the ED, according to
the judgement of the local radiologist together with at least
two of the following signs or symptoms: cough, sputum
production, temperature of >38°C or <36.1°C, auscultatory
findings consistent with pneumonia, leukocytosis (>10.0 9
109 white blood cells (WBCs)/L) or leukopenia (<4.5 9
109 WBCs/L), a C-reactive protein level more than three
times the upper limit of normal, hypoxaemia with PO2 <
60 mmHg while the patient was breathing room air, or
dyspnoea/tachypnoea.
The causative microorganism of CAP was considered to be
‘definite’ if it was cultured from blood or any other sterile fluid,
or if the urinary antigen test was positive (either for Legionella
or pneumococcal antigen with the ICA or with the UAD). A
causative microorganism of CAP was considered to be
‘probable’ in the absence of a definite pathogen, and if it was
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present as the dominant flora in the sputum culture.
Pneumococcal CAP was defined as CAP with S. pneumoniae
as the ‘definite’ or ‘probable’ causative microorganism. If
S. pneumoniae was cultured/diagnosed together with another
pathogen, CAP was not considered to be pneumococcal.
Data analysis
The SPSS statistical package (version 20.0; SPSS, Chicago, IL,
USA) was used for the analyses. Potential predictors were
analysed in the groups with and without pneumococcal CAP by
univariate analysis followed by multivariate analysis, to select
the independent predictors. The group ‘without pneumococcal
CAP’ consisted intentionally of a combination of patients with
CAP caused by other pathogens and with unknown aetiology,
because the prediction model was developed for use in the ED.
At the moment of presentation, it is unknown whether the
CAP patient will belong to the ‘known’ or ‘unknown’ aetiology
group, and adjustment of the study domain on the basis of this
knowledge is therefore not reasonable. For univariate analysis,
Pearson’s chi-square test, a two-sample t-test or the Mann–
Whitney U-test were used, depending on the data and
distribution. All continuous variables were checked for the
linearity assumption, and used as such whenever possible. The
variable ‘leukocyte count’ had to be converted to a categorical
variable in three categories (<4.5 9 109 WBCs/L, 4.5–
10.0 9 109 WBCs/L, and >10.0 9 109 WBCs/L).
The variable ‘respiratory rate’ was converted to a
dichotomous variable, because of many missing values
(approximately 57%). It was assumed that this value would
have been documented if the respiratory rate had been
≥30 breaths/min. Therefore, all missing values were
considered as respiratory rates of <30 breaths/min. For all
other missing values for the determinants, single imputation by
regression methods was used.
The potential predictor variables were entered into a
multivariate model to determine the independent predictors
of pneumococcal CAP by using backward logistic regression
based on the likelihood ratio, with a p-value of 0.05 being
considered significant. This resulted in a probability score that
was checked with the probability of pneumococcal pneumonia
in a calibration plot. Also, the Hosmer–Lemeshow test was
used to check calibration. A receiver operating characteristic
curve was used to investigate discrimination. The model was
evaluated for different probability cut-off values in order to
create a high chance of predicting pneumococcal pneumonia
for a reasonable proportion of patients. The relevance of this
model in daily practice was evaluated by presenting the
sensitivity, specificity and positive and negative predictive
values for the various cut-off values.
Results
Study population
A total of 1758 patients with a clinical suspicion of CAP were
included, of whom 630 did not have an infiltrate on the chest
X-ray at presentation, three did not fulfil the inclusion criteria,
65 had one or more exclusion criteria, and three did not have
one of the reference tests performed. This resulted in a study
population of 1057 patients with radiographically confirmed
CAP.
Aetiology
Blood cultures were available for 894 patients (84.6%), sputum
cultures for 545 patients (51.6%), Legionella urinary antigen test
results for 703 patients (66.5%), ICA results for 1032 patients
(97.6%) (978 from centrally processed samples and 54 from
locally processed samples), and UAD results for 979 cases
(92.6%). Urine samples from 78 subjects were not available for
central processing.
An aetiological cause of CAP could be determined in 461
patients (43.6%) (Table 1). The most common causative
pathogen was S. pneumoniae (328 patients, 31.0%), followed
by Haemophilus influenzae. In total, there were 228 UADs with
a positive result and 200 ICAs with a positive result; the
overlap of the various diagnostic modalities for S. pneumoniae
is shown in Fig. 1. Three CAP episodes had a positive urine
antigen test result for both S. pneumoniae and Legionella, and
one episode had an Escherichia coli bacteraemia and a positive
pneumococcal urinary antigen test result. In all four episodes,
both the ICA and the UAD test gave positive results. These
TABLE 1. Aetiology of 1057 patients with confirmed com-
munity-acquired pneumonia in the emergency department
Pathogen
Definite
pathogena
Probable
pathogenb
Total (n = 1057),
no. (%)
Streptocccus pneumoniae 321 7 328 (31.0)
Haemophilus influenzae 1 37 38 (3.6)
Legionella pneumophila 27 – 27 (2.6)
Pseudomonas aeruginosa 4 4 8 (0.8)
Moraxella catarrhalis – 6 6 (0.6)
Klebsiella species 3 7 10 (0.9)
Escherichia coli 3 6 9 (0.9)
Staphylococcus aureus 4 6 10 (0.9)
Mixed aetiologyc 6 – 6 (0.6)
Other 6 13 19 (2.4)
Unknown 596 (56.4)
aPositive blood culture or other sterile site or positive urinary antigen test result
(either immunochromatographic assay (ICA) or urinary antigen detection test
(UAD)).
bIn the absence of a definite pathogen and if the pathogen is the dominant flora in
the sputum culture.
cConsisting of: two blood cultures with two pathogens, one S. pneumoniae positive
blood culture with a positive Legionella antigen test, one E. coli positive blood
culture with a positive ICA and UAD, two positive ICA and UAD tests with a
positive Legionella antigen test.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1316–1322
1318 Clinical Microbiology and Infection, Volume 20 Number 12, December 2014 CMI
four cases were not considered to be true pneumococcal CAP
(but were counted as ‘mixed aetiology’), as the ultimate goal of
our prediction rule was to identify patients eligible for
narrow-spectrum antibiotics.
Predictors for pneumococcal CAP
In univariate analysis, 11 determinants were associated with
pneumococcal CAP (Table 2). Pneumococcal immunization
occurred in only three subjects, all in the ‘non-pneumococcal
CAP’ group. In multivariate logistic regression analysis, nine
predictors for pneumococcal CAP were identified (Table 3).
The mean predicted probabilities correlated reasonably well
with the observed probabilities, and the Hosmer–Lemeshow
test had a p-value of 0.258, both indicating fair calibration of
the model. The area under the receiver operating character-
istic curve was 0.692 (95% CI 0.657–0.726). With a probability
cut-off value of ≥0.50, the positive predictive value was 68%.
Decreasing the cut-off value resulted in higher sensitivity and a
higher negative predictive value, and increasing the cut-off
value had the opposite effect (Table 4). However, no satisfying
cut-off value could be determined for the use of this model in
daily clinical practice.
n = 14
n = 34
n = 16
n = 84
FIG. 1. Diagnosing Streptococcus pneumoniae. Total N = 324. Four of
these subjects were not counted as having ‘pneumococcal commu-
nity-acquired pneumonia (CAP)’, because of a positive Legionella
urinary antigen test result or Escherichia coli bacteraemia at the same
time. One subject was diagnosed as having pneumococcal CAP by a
positive pleural fluid culture only. BC, blood culture; ICA, urinary
immunochromatographic assay (BinaxNOW) for S. pneumoniae; UAD,
serotype-specific urinary antigen detection test; pos., positive result
for S. pneumoniae.
TABLE 2. Baseline table; univariate analysis of potential predictors
Determinants Pneumococcal CAP (n = 328) Other CAP (n = 729) p-Value
Male gender, no. (%) 182 (55.5) 480 (65.8) 0.002a
Present smoker, no. (%) 102 (31.1) 221 (30.3) 0.829
Comorbidities, no. (%)
COPD 119 (36.3) 263 (36.1) 0.945
Cardiovascular diseases 188 (57.3) 424 (58.2) 0.840
Diabetes mellitus 48 (14.6) 114 (15.6) 0.713
Renal failure 9 (2.7) 36 (4.9) 0.137
Malignancyb 23 (7.0) 60 (8.2) 0.538
Immunocompromised 31 (9.5) 69 (9.5) 1.000
Drug use, no. (%)
Proton-pump inhibitors 82 (25.0) 195 (26.7) 0.597
NSAIDs; not acetylsalicylic acid 21 (6.4) 68 (9.3) 0.121
Psychoactive drugs or benzodiazepines 59 (18.0) 145 (19.8) 0.501
Antibiotic pretreatmentc, no. (%) 78 (23.8) 258 (35.4) 0.000a
Recurrent pneumoniasd, no. (%) 55 (16.8) 139 (19.1) 0.392
Pneumococcal immunization, no. (%) 0 (0.0) 3 (0.4) 0.456
Auscultation consistent with pneumonia, no. (%) 258 (78.7) 562 (77.1) 0.633
Symptoms at presentation, no. (%)
Altered mental status 51 (15.5) 102 (13.9) 0.509
Cough 267 (81.4) 555 (76.1) 0.066
Sputum production 148 (45.1) 319 (43.8) 0.688
Fever 207 (63.1) 427 (58.3) 0.175
Dyspnoea 255 (77.7) 575 (78.9 0.686
Pleuritic pain 82 (25.0) 120 (16.5) 0.001a
Chills 50 (15.2) 107 (14.6) 0.852
Respiratory rate of > 30 breaths/min 42 (12.8) 63 (8.6) 0.045a
Duration of complaints before admission (days) median (IQR) 3 (2–7) 4 (2–8) 0.002a
Age (years) median (IQR) 67 (55–77) 70 (57–79) 0.047a
Systolic blood pressure (mmHg) mean (SD) 127  26.2 133  23.6 0.001a
O2 saturation (%) median (IQR) 94 (90–96) 94 (91–96) 0.286
Pulse rate (beats/min) mean (SD) 103  20.8 99  20.6 0.007a
White blood cells (9109/L) median (IQR) 15.8 (11.7–21.4) 12.8 (9.5–16.5) 0.000a
CRP (mg/L) median (IQR) 186 (80–323) 128 (52–229) 0.000a
Urea/BUN (mM) median (IQR) 7.4 (5.2–11.2) 6.6 (4.7–9.7) 0.009a
Sodium (mM) median (IQR) 136 (134–139) 137 (134–140) 0.967
Glucose (mM) median (IQR) 7.3 (6.2–8.8) 7.1 (6.0–8.5) 0.163
Haematocrit median (IQR) 0.39 (0.36–0.43) 0.40 (0.36–0.43) 0.788
BUN, blood urea nitrogen; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein IQR, interquartile range;; NSAID,
non-steroidal anti-inflammatory drug; SD, standard deviation.
aSignificant difference between the group with ‘pneumococcal CAP’ and the group with ‘other CAP’.
bActive or diagnosed in the year before admission.
cIn the 2 weeks before admission.
dTwo or more pneumonias requiring hospitalization during the last 5 years.
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Discussion
This study of 1057 patients failed to demonstrate that clinical
criteria can be used to predict a pneumococcal aetiology in
patients with CAP presenting at the ED. The clinical value of
predicting a pneumococcal aetiology of CAP lies in the
possibility of minimizing empirical broad-spectrum antibiotic
treatment before the microbiological test results are available.
For this purpose, a prediction rule should have a high positive
predictive value, in order to avoid inappropriate therapy in
severely ill patients. However, in this study, the combination of
predictors and the cut-off value needed to reach a 100%
positive predictive value implied that only 1.5% of all CAP
patients in the ED would be classified as having pneumococcal
CAP. Using lower cut-off values would inevitably result in
misclassification of patients and the potential prescription of
incorrect antibiotic treatment.
So, despite the inclusion of 1057 patients with CAP, with
328 diagnosed as having pneumococcal CAP, we were
unable to develop a useful clinical prediction rule. Previously,
Bohte et al. [16] developed a scoring system to predict
S. pneumoniae as the causative organism of CAP. However,
that rule can only be applied if a sputum Gram stain result is
available, which is not the case in c. 50% of all CAP patients
[19]. Furthermore, this rule was designed by comparing data
from 79 patients with pneumococcal CAP with those from
83 patients with CAP caused by other pathogens, excluding
the information from 106 patients in whom a causative
pathogen could not be detected. From our point of view,
this selection of patients does not reflect daily practice,
because it is not known beforehand whether a pathogen can
be detected.
Other investigators have also failed to accurately predict the
aetiology of CAP on the basis of clinical patterns or radiographic
features [14,15,20,21]. Ruiz-Gonzales et al. [11] developed a
bedside rule to distinguish ‘virus-like’ pneumonia (including
Mycoplasma pneumoniae and Legionella pneumophila) and bacte-
rial pneumoniawith three clinical predictors. They used different
scores with sensitivities between 57% and 89% and specificities
between 63% and 94%. However, this rule was developed with a
study population of 103 patients only (48 with virus-like
pneumonia and 37with bacterial pneumonia), excluding patients
with unknown aetiology (n = 18), which, as mentioned above,
does not correspond to daily practice in the ED.
We had expected to be more successful in our efforts to
predict pneumococcal CAP, because of our large sample size
and high proportion of patients with pneumococcal CAP,
owing to the addition of the UAD, but the nine independent
predictors had no useful predictive value for applying this rule
in daily practice. This leaves rapid pneumococcal antigen
detection in urine as the only opportunity to start nar-
row-spectrum antibiotics directly at admission. In our cohort,
the ICA could have allowed narrow-spectrum antibiotics to be
started in 18.9% of the study population (n = 200) when used
as a ‘point-of-care’ test in the ED.
In a study using the ICA as a treatment decision strategy,
amoxycillin was prescribed to 48 of 219 patients with CAP on
the basis of ICA results, and appeared to be as effective as
clarithromycin in all other patients [22]. In two other
observational studies, only 31.5% and 35% of the patients
with positive ICA results switched to (more) targeted
antibiotic treatment [23,24].
TABLE 3. Independent predictors of pneumococcal community-acquired pneumonia
B p-Value OR 95% CI for OR
Male gender 0.470 0.001 0.625 0.471–0.830
Antibiotic pretreatment 0.516 0.001 0.597 0.435–0.818
Cough 0.435 0.014 1.544 1.091–2.186
Pleuritic pain 0.415 0.016 1.515 1.079–2.128
Days complaints 0.019 0.028 0.981 0.964–0.998
Systolic BP (mmHg) 0.008 0.005 0.992 0.986–0.998
CRP (mg/L) 0.003 0.000 1.003 1.002–1.004
Sodium (mM) 0.035 0.027 1.036 1.004–1.069
WBC: 4.5–10 9 109/L (ref) NA NA NA NA
WBC: ≤4.5 9 109/L 0.960 0.047 2.611 1.013–6.731
WBC: ≥10 9 109/L 0.791 0.000 2.206 1.516–3.212
Constant 5.582 0.014 0.004
B, coefficient in prediction formula; BP, blood pressure; CRP, C-reactive protein; NA, not applicable; ref, reference; WBC, white blood cell.
TABLE 4. Diagnostic value for prediction model at various
cut-off values
Cut-off
value N Sensitivity (%) Specificity (%) PPV (%) NPV (%)
≥0.3 502 65.9 60.8 43.0 79.8
≥0.4 265 42.1 82.6 52.1 76.0
≥0.5 120 25.0 94.8 68.3 73.7
≥0.6 54 13.1 98.5 79.6 71.6
≥0.7 16 4.9 100.0 100.0 70.0
N, number of patients with cut-off value above the set limit; NPV, negative
predictive value; PPV, positive predictive value.
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In another study, patients with CAP were—after reaching
clinical stabilization—randomized to empirical treatment
(broad-spectrum b-lactam + macrolide/levofloxacin) or tar-
geted treatment (amoxycillin) [25]. Of the 88 patients in the
targeted treatment arm, 22 (25%) were switched to amoxy-
cillin after an average of 5 days, because of a positive
pneumococcal ICA result at admission. Three of those patients
experienced a clinical relapse after antibiotic switch, and the
authors concluded that narrowing treatment on the basis of
ICA results carries a higher risk of clinical relapse. However,
this conclusion was based on relatively few patients, and
amoxycillin was started after the patient was considered to be
clinically stable. Therefore, we feel that these conclusions
should be interpreted with caution.
The strengths of our study include the size of our study
population, the uniform methods for data collection, and the
high proportion of episodes categorized as pneumococcal CAP
owing to the addition of a new, highly sensitive, diagnostic test.
Our study also has some limitations. First, we were not able to
perform the UAD in all cases, which might have created a
partial verification bias. However, this accounts for only 78
cases (7.4%), and we used the combination of results of the
other diagnostic tools (ICA, blood culture, and sputum
culture) from the local laboratory. Therefore, we believe that
the risk of bias is very limited. Furthermore, there were some
missing data among the determinants, which were imputed
with regression methods.
In conclusion, clinical criteria cannot be used to diagnose
pneumococcal CAP, but urinary antigen testing could offer the
possibility of safely avoiding broad-spectrum antibiotic therapy
in c. 20% of episodes of CAP.
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